The primary aim of this study was to evaluate the effectiveness of selected renal dysfunction biomarkers (cystatin C, KIM-1, and NGAL) in dogs with stage B2 DCM compared to a healthy control group. This evidence concerns the gene HAVCR1 and familial dilated cardiomyopathy.